DigestRedComo funciona
Red
/
Empresas
Gu
No verificado

Guardant Health, Inc.

Sobre qué escribimos

BiotecnologíaIndustriaOncologíaSaludSanidad

108 Comunicados de prensa

Ver todos los comunicados de prensa
10/03/2026
Mercado laboral
Industria
Oncología
Salud
Sanidad
Gestión empresarial
Biotecnología
Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics
Fuente
Guardant Health, Inc.
Editor
Business Wire
1.00
0
04/03/2026
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America
Fuente
Guardant Health, Inc.
Editor
Business Wire
1.00
0
03/03/2026
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened
Fuente
Guardant Health, Inc.
Editor
Business Wire
1.00
0
27/02/2026
Mercado de valores
Finanzas
Sanidad
Salud
Oncología
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
Guardant Health, Inc.
Editor
Business Wire
1.00
0
19/02/2026
Biotecnología
Material médico sanitario
Salud
Oncología
Web y redes sociales
Telefonía
Mercado de valores
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
Fuente
Guardant Health, Inc.
Editor
Business Wire
1.00
0
03/02/2026
Técnica
Asociaciones/Profesionales
Software
Salud
Farmacéutica
Oncología
Eventos
Guardant Health to Participate in Upcoming Investor Conferences
Fuente
Guardant Health, Inc.
Editor
Business Wire
1.00
0
02/02/2026
Industria
Oncología
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
Fuente
Guardant Health, Inc.
Editor
Business Wire
1.00
0
29/01/2026
Biotecnología
Farmacéutica
Salud
Oncología
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Fuente
Guardant Health, Inc.
Editor
Business Wire
1.00
0
22/01/2026
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Industria
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Fuente
Guardant Health, Inc.
Editor
Business Wire
1.00
0
19/01/2026
Oncología
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Mercado laboral
Industria
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
Fuente
Guardant Health, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0